Evaluation of Diabetes Care at Austrian GPs (DCA09)

This study has been terminated.
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00979394
First received: September 17, 2009
Last updated: August 16, 2010
Last verified: August 2010
  Purpose

This registery should show the medical care of patient with Type 2 Diabetes (T2D) at GP-offices. Furthermore data of co morbidities and risk factors should be evaluated. Objectives of this NIS (cross-sectional study) are:

  • To evaluate which characteristics or co-morbidities are being existent for patient with T2D at GP level,
  • To evaluate representative profile of patient with T2D in Austria,
  • To evaluate which medical therapies are used.

Condition
Type 2 Diabetes

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diabetes Care Austria 2009

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Evaluate characteristics or co morbidities being existent for patient with T2D at GP [ Time Frame: Once per patient ] [ Designated as safety issue: No ]

Enrollment: 1513
Study Start Date: October 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Patients with type 2 diabetes

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

GPs

Criteria

Inclusion Criteria:

  • Diabetes mellitus type II

Exclusion Criteria:

  • Diabetes mellitus type I
  • Gestation diabetes
  • Induced diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00979394

Sponsors and Collaborators
AstraZeneca
Bristol-Myers Squibb
Investigators
Study Chair: Bernhard Ludvig General Hospital Vienna
Study Chair: Guntram Schernthaner Krankenanstalt Rudolfsstiftung
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT00979394     History of Changes
Other Study ID Numbers: NIS-CAT-DUM-2009/1
Study First Received: September 17, 2009
Last Updated: August 16, 2010
Health Authority: Austria: Ethikkommission

Keywords provided by AstraZeneca:
Diabetes Care at GPs in Austria
Characteristic of diabetes patients at GPs in Austria

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on August 28, 2014